Bortezomib plus low dose cytarabine in Int-2 and high risk MDS. Interim results of a phase I/II trial by the GFM

被引：0
|
作者：
Natarajan, Shahti [1 ]
Fenaux, Pierre [1 ]
Vey, Norbert [1 ]
Guerci, A. [1 ]
Coulibaly, I. [1 ]
Charbonnier, A. [1 ]
Ravoet, C. [1 ]
Courby, S. [1 ]
Etienne, G. [1 ]
Chaury, M. P. [1 ]
Cheze, S. [1 ]
Stamatoullas, A. [1 ]
Legros, L. [1 ]
Berger, E. [1 ]
Lescoute, A. [1 ]
Vaultier, S. [1 ]
Dreyfus, F. [1 ]
机构：
[1] Grp Francophone Myelodysplasies, Paris, France
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1453
引用
收藏
页码：435A / 435A
页数：1
相关论文
共 50 条
  • [41] The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial
    Swaminathan, Mahesh
    Kantarjian, Hagop
    Daver, Naval
    Borthakur, Gautam
    Ghanian, Maro
    Kadia, Tapan
    DiNardo, Courtney
    Jain, Nitin
    Estrov, Zeev
    Ferrajok, Alessandra
    Garcia-Manero, Guillermo
    Konopleva, Marina
    Andreeff, Michael
    Pemmaraju, Naveen
    Jabbour, Elias
    Alvarado, Yesid
    Wierda, William
    Pinsoy, Maria Rhona
    Ravandi, Farhad
    Cortes, Jorge
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S3 - S3
  • [42] Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma
    Nishihori, Taiga
    Alekshun, Todd J.
    Shain, Kenneth
    Sullivan, Daniel M.
    Baz, Rachid
    Perez, Lia
    Pidala, Joseph
    Kharfan-Dabaja, Mohamed A.
    Ochoa-Bayona, Jose L.
    Fernandez, Hugo F.
    Yarde, Danielle N.
    Oliveira, Vasco
    Fulp, William
    Han, Gang
    Kim, Jongphil
    Chen, Dung-Tsa
    Raychaudhuri, Jyoti
    Dalton, William
    Anasetti, Claudio
    Alsina, Melissa
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 (05) : 553 - 563
  • [43] ASSOCIATION OF AZACITIDINE AND LENALIDOMIDE (COMBINATION VS SEQUENTIAL TREATMENT) FOR HIGH-RISK MYELODYSPLASTIC SYNDROMES (IPSS RISK: HIGH OR INT-2): A PHASE II CLINICAL AND BIOLOGICAL STUDY
    Finelli, C.
    Clissa, C.
    Follo, M. Y.
    Stanzani, M.
    Parisi, S.
    Avanzini, P.
    Bosi, C.
    Castagnari, B.
    Candoni, A.
    Crugnola, M.
    Giannini, M. B.
    Gobbi, M.
    Leonardi, G.
    Rigolin, G. M.
    Russo, D.
    Tosi, P.
    Visani, G.
    Cocco, L.
    Cavo, M.
    HAEMATOLOGICA, 2015, 100 : 52 - 53
  • [44] , HYPOFRACTIONATED RADIOTHERAPY FOR LOW RISK PROSTATE CANCER: PRELIMINARY RESULTS OF A PHASE I/II TRIAL
    Menkarios, C.
    Nguyen, D. H. A.
    Vigneault, E.
    Brochet, N.
    Bahary, J. P.
    Jolicoeur, M.
    Nguyen, T. Van
    Beauchemin, M. C.
    Fortin, B.
    Fortin, M. A.
    Lambert, C.
    RADIOTHERAPY AND ONCOLOGY, 2009, 92 : S42 - S42
  • [45] TOSEDOSTAT PLUS LOW DOSE CYTARABINE COMBO INDUCES A HIGH RATE OF RESPONSES THAT CAN BE PREDICTED BY GENETIC PROFILING IN AML: FINAL RESULTS OF A PHASE II MULTICENTER STUDY
    Visani, G.
    Loscocco, F.
    Fuligni, F.
    Zuffa, E.
    Sensi, A.
    Zaccaria, A.
    Musuraca, G.
    Giannini, B.
    Lucchesi, A.
    Fabbri, F.
    Mianulli, A. M.
    Tosi, P.
    Tonelli, M.
    Candoni, A.
    Fanin, R.
    Sparaventi, G.
    Gobbi, M.
    Clavio, M.
    Rocchi, M.
    Piccaluga, P.
    Isidori, A.
    HAEMATOLOGICA, 2015, 100 : 215 - 215
  • [46] TOSEDOSTAT PLUS LOW DOSE CYTARABINE COMBO INDUCES A HIGH RATE OF RESPONSES THAT CAN BE PREDICTED BY GENETIC PROFILING IN AML: FINAL RESULTS OF A PHASE II MULTICENTER STUDY
    Isidori, A.
    Loscocco, F.
    Fuligni, F.
    Zuffa, E.
    Sensi, A.
    Zaccaria, A.
    Musuraca, G.
    Giannini, B.
    Lucchesi, A.
    Fabbri, F.
    Mianulli, A. M.
    Tosi, P.
    Tonelli, M.
    Candoni, A.
    Fanin, R.
    Sparaventi, G.
    Gobbi, M.
    Clavio, M.
    Rocchi, M.
    Piccaluga, P. P.
    Visani, G.
    HAEMATOLOGICA, 2015, 100 : 10 - 10
  • [47] PHASE I/II STUDY OF PANOBINOSTAT FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH RISK MDS OR AML: INITIAL RESULTS FROM THE PHASE I PART OF THE PANOBEST TRIAL
    Bug, G.
    Burchert, A.
    Kroeger, N.
    Duenzinger, U.
    Wolf, A.
    Huenecke, S.
    Bader, P.
    Serve, H.
    Ottmann, O.
    HAEMATOLOGICA, 2013, 98 : 370 - 370
  • [48] Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents
    Montalban-Bravo, Guillermo
    Jabbour, Elias
    Chien, Kelly S.
    Borthakur, Gautam
    Estrov, Zeev
    Kadia, Tapan M.
    Ravandi, Farhad
    Pemmaraju, Naveen
    Nogueras-Gonzalez, Graciela
    Schneider, Heather
    John, Rosmy
    Meyer, Meghan Anne
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Dong, Xiao Qin
    BLOOD, 2023, 142
  • [49] Phase I trial combining ipilimumab plus high dose stereotactic radiation: Results and serum immune correlates
    Tang, Chad
    Welsh, James William
    de Groot, Patricia
    Massarelli, Erminia
    Chang, Joe Y.
    Hess, Kenneth R.
    Curran, Michael A.
    Cabanillas, Maria E.
    Subbiah, Vivek
    Fu, Siqing
    Tsimberidou, Apostolia Maria
    Karp, Daniel D.
    Gomez, Daniel Richard
    Komaki, Ritsuko
    Sharma, Padmanee
    Naing, Aung
    Hong, David S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] Sequential Azacitidine and High-Dose Lenalidomide for Relapsed and Refractory High-Risk MDS and AML: Interim Analysis of a Phase 2 Study
    Pollyea, Daniel A.
    Smith, Clayton A.
    Nguyen, Vu H.
    Fullerton, Aaron
    Schatz, Derek
    Bedrick, Edward J.
    Gutman, Jonathan A.
    BLOOD, 2014, 124 (21)
12345